Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US89422G1076
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000P9D6W9
TVTX
Travere Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Travere Therapeutics Inc
ISIN
US89422G1076
TICKER
TVTX
MIC
XNAS
REUTERS
TVTX.OQ
BLOOMBERG
TVTX US
Tue, 03.11.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Bioph...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.11.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.10.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in i...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 24.10.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 202...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.10.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock a...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 02.10.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.09.2026       Travere Therapeutics
US89422G1076

NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate gov...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.09.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.09.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replay...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 11.09.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to th...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.08.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biophar...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Our performance reflects...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.07.2026       Travere Therapeutics
US89422G1076

NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate go...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.07.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to in...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the t...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reduc...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 02.06.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all market...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA n...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, a...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its first quarter 2026 financial results and provided a corporate update. “This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI’s foundational position in IgAN, and the advancement of...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in in...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,420 shares of its common stock. These inducement RSUs are subject to the...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is the first and only medicine approved by t...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of meaningful advancement for Travere, strengthening both our commercial execution and long-term growth outlook,” said Eric Dube, Ph.D., president and chief executive officer of Tra...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 49,200 shares of its common stock. These inducement RSUs are subject to t...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be avail...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.01.2026       Travere Therapeutics
US89422G1076

SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have infor...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Travere Therapeutics
US89422G1076

Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more de...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Travere Therapeutics
US89422G1076

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide y...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately $127 million. For the fiscal year 2025, the Company expects total U.S. net product sales to be approximately $410 million. The Company...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/e...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 20,300 shares of its common stock. These inducement RSUs are subject to...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,700 shares of its common stock. These inducement RSUs are subject to...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were significantly more likely to reach proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan,...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 TD Cowen Immunology &...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. “We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dia...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.10.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9. In focal segmental glomerulosclerosis (FSGS), the Company will present: A late-breaking analysis from the DU...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.10.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 228,600 shares of its common stock to 43 new employees, consisting of inducement stock options to purchase an aggregate of 50,000 shares of common stock a...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.09.2025       Travere Therapeutics
US89422G1076

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidel...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.09.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 69,300 shares of its common stock. These inducement RSUs are subject to t...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink